January 14, 2020

Fusion Pharmaceuticals Announces Investment From Canada Pension Plan Investment Board (CPPIB)

Hamilton, ON & Boston, MA – January 13, 2020 – Fusion Pharmaceuticals Inc., a clinical-stage precision oncology company developing next-generation radiopharmaceuticals, t...
Read more
January 13, 2020

Fusion Pharmaceuticals To Present At The 38th Annual J.P. Morgan Healthcare Conference

Hamilton, ON & Boston, MA – January 10, 2020 – Fusion Pharmaceuticals Inc., a privately-held, clinical-stage precision oncology company developing next-generation radiopha...
Read more
January 9, 2020

Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020

BOSTON, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeuti...
Read more
January 9, 2020

Strongbridge Biopharma plc Announces Preliminary Fourth Quarter and Full-Year 2019 Financial Results and Provides Update on Corporate Priorities

~ Expects to Report KEVEYIS®(dichlorphenamide) Fourth Quarter 2019 Revenue of Approximately $5.6 Million and Full-Year 2019 Revenue of Approximately $21.7 Million, a 29 Percent...
Read more
January 8, 2020

Targovax and IOVaxis Therapeutics enters Option Agreement for TG mutant RAS vaccine license and clinical development in China

IOVaxis buys an exclusive option to license the TG01/02 cancer vaccines for China, Hong Kong, Macau and Singapore, for a fee of USD 250.000 If exercised, the lic...
Read more
January 7, 2020

Oncopeptides strengthens its regulatory function by appointing Karin Eklund Vanderpol as Head of Regulatory Affairs

STOCKHOLM — January 7, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Karin Eklund Vanderpol has been appointed as head of regulatory affairs of Onc...
Read more
December 20, 2019

GenSight Biologics obtains €15 million in financing through a bond issuance from Kreos Capital and a reserved capital increase from Sofinnova and 3SBio

First tranche of €6 million bond issuance and capital increase of €9 million Potential future financings as a second tranche of €4 million and an additional tr...
Read more
December 18, 2019

BONESUPPORT appoints Kristina Ingvar to Executive Vice President Quality Management & Regulatory Affairs

Lund, Sweden, 15:00 CET, 18 December 2019 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, announces changes in its leadership tea...
Read more
December 18, 2019

Update on progress for drug development programs VP01 (C21) and VP02 (IMiD)

Gothenburg, December 18, 2019 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announce...
Read more
December 18, 2019

Nordic Nanovector awarded NOK 12 million in funding from the Norwegian Research Council to advance Alpha37, a targeted alpha therapy for B-cell cancers

Oslo, Norway, 18 December 2019 Nordic Nanovector ASA (OSE: NANO) announces that its research and development project Nanoyield has received a non-dilutive funding of NOK 1...
Read more